BioMarin Phase 3 Study of Pegvaliase for Phenylketonuria (PKU) Meets Primary Endpoint of Blood Phenylalanine (Phe) Reduction (p<0.0001)
Go back to BioMarin Phase 3 Study of Pegvaliase for Phenylketonuria (PKU) Meets Primary Endpoint of Blood Phenylalanine (Phe) Reduction (p<0.0001)| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 56.50 +0.60 (1.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.90 | 52 Week High | $108.96 | |||
| Open | $55.80 | 52 Week Low | $62.12 | |||
| Day High | $57.00 | P/E | N/A | |||
| Day Low | $55.74 | EPS | $-1.27 | |||
| Volume | 1,987,924 | |||||
